CANCER

Bloodwise 16
STRATEGIC REPORT
In an era where the old model of drug development
takes too long and is simply too expensive – and
in a year when the Cancer Drugs Fund has been
challenged and will continue to be challenged – TAP is
a demonstration of a new, more cost effective way to
deliver new treatments.
We plan to progress conversations with the National
Institute for Clinical Excellence (NICE) to make some
new drugs available earlier than normal, for discrete
groups of patients who need them urgently.
to cover the funding of the hub for five years from
January 2015 and the centres for two years, pending a
full review of the centres in 2016. A TAP manager has
been recruited to ensure that the key metrics that will
demonstrate the success of TAP are achieved.
With TAP and our investment in non-TAP trials, this
year has seen our biggest investment ever in clinical
trials of £9.5 million.
We committed further funding of £6.3 million to TAP
The route to de-costing
medicines is de-risking them
for pharmaceuticals. This
means deeper development by
the academic sector and the
uptake by industry of only the
medicines that are most likely
to be successful and therefore
licensed. This means no loss
leaders and cheaper drugs.
Chris Bunce, Research Director.
Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089
Registered charity 216032 (England & Wales) SC037529 (Scotland)